Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Capital Expenditures (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Capital Expenditures data on record, last reported at $6.3 million in Q1 2026.

  • On a quarterly basis, Capital Expenditures rose 63.1% to $6.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $10.0 million, a 12.27% decrease, with the full-year FY2025 number at $7.5 million, down 42.8% from a year prior.
  • Capital Expenditures reached $6.3 million in Q1 2026 per PCVX's latest filing, up from $2.0 million in the prior quarter.
  • Over the last five years, Capital Expenditures for PCVX hit a ceiling of $13.1 million in Q3 2024 and a floor of -$5.2 million in Q4 2024.
  • A 5-year average of $2.9 million and a median of $2.1 million in 2025 define the central range for Capital Expenditures.
  • On a YoY basis, Capital Expenditures climbed as much as 9861.4% in 2024 and fell as far as 199.49% in 2024.
  • Tracing PCVX's Capital Expenditures over 5 years: stood at $1.1 million in 2022, then skyrocketed by 360.88% to $5.3 million in 2023, then plummeted by 199.49% to -$5.2 million in 2024, then soared by 137.69% to $2.0 million in 2025, then surged by 221.98% to $6.3 million in 2026.
  • Business Quant data shows Capital Expenditures for PCVX at $6.3 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.